When Digital Biomarkers Drift: A Critical Review of Temporal, Technological, Behavioral, and Population Instability in AI Models for Neurodegenerative Disease

Authors

  • Olaitan Ebenezer Oluwadare Applied Mathematics Department, School of Physics, Engineering, Mathematics and Computer Science, Delaware State University, Dover, Delaware, USA Author
  • Anyebe Daniel Ameh College of Professional Studies, University of Denver, Denver, Colorado, USA Author
  • Abdul-Basid Yakubu School of Natural Sciences, University of Chester, Chester, England, United Kingdom Author
  • Faith Uzochi Sunday College of Professional Studies, University of Denver, Denver, Colorado, USA Author

DOI:

https://doi.org/10.64229/8m5kv497

Keywords:

Digital biomarkers, Neurodegenerative diseases, Artificial intelligence, Biomarker drift, Dataset shift, Longitudinal validation

Abstract

Digital biomarkers derived from smartphones, wearables, and connected sensors are increasingly combined with artificial intelligence (AI) to detect and monitor neurodegenerative diseases, yet the signals on which these models depend are not static. This critical review, based on a structured search of biomedical, engineering, and regulatory literature, examines four interacting sources of instability: temporal drift arising from disease progression, aging, treatment, and symptom fluctuation; technological drift caused by changes in devices, sensors, software, and processing pipelines; behavioral and contextual drift associated with routines, adherence, engagement, and missing data; and population drift that arises when deployment cohorts differ from narrow development cohorts. We map these sources onto established machine-learning concepts, including covariate shift, label shift, and concept drift, and summarize disease- and modality-specific evidence in Parkinson disease, Alzheimer disease, Huntington disease, and related conditions. Across the literature, separating genuine disease progression from measurement-related, behavioral, and population-related change remains difficult, and validation based on random data splits, short follow-up, homogeneous cohorts, and single devices can overestimate durability. These limitations can produce false deterioration signals, unstable individual predictions, and inequitable performance after deployment. We propose a Detect → Attribute → Quantify → Adapt → Validate → Monitor (DAQAV-M) framework with illustrative operational criteria, attribution strategies, and version-controlled updating rules, and we position it relative to existing dataset-shift, model-monitoring, and regulatory lifecycle approaches. Trustworthy digital biomarkers require lifecycle validation that separates biomarker validity from model performance and tests stability within individuals, across technologies, and across diverse populations.

References

[1]Dorsey ER, Papapetropoulos S, Xiong M, Kieburtz K. The first frontier: Digital biomarkers for neurodegenerative disorders. Digital Biomarkers, 2017, 1(1), 6-13. DOI: 10.1159/000477383

[2]Coravos A, Khozin S, Mandl KD. Developing and adopting safe and effective digital biomarkers to improve patient outcomes. npj Digital Medicine, 2019, 2, 14. DOI: 10.1038/s41746-019-0090-4

[3]Vasudevan S, Saha A, Tarver ME, Patel B. Digital biomarkers: Convergence of digital health technologies and biomarkers. npj Digital Medicine, 2022, 5, 36. DOI: 10.1038/s41746-022-00583-z

[4]Macias Alonso AK, Hirt J, Woelfle T, Janiaud P, Hemkens LG. Definitions of digital biomarkers: A systematic mapping of the biomedical literature. BMJ Health & Care Informatics, 2024, 31(1), e100914. DOI: 10.1136/bmjhci-2023-100914

[5]Espay AJ, Bonato P, Nahab FB, Maetzler W, Dean JM, Klucken J, et al. Technology in Parkinson's disease: Challenges and opportunities. Movement Disorders, 2016, 31(9), 1272-1282. DOI: 10.1002/mds.26642

[6]Hansen C, Sanchez-Ferro A, Maetzler W. How mobile health technology and electronic health records will change care of patients with Parkinson's disease. Journal of Parkinson's Disease, 2018, 8(s1), S41-S45. DOI: 10.3233/JPD-181498

[7]Andrzejewski KL, Dowling AV, Stamler D, Felong TJ, Harris DA, Wong C, et al. Wearable sensors in Huntington disease: A pilot study. Journal of Huntington's Disease, 2016, 5(2), 199-206. DOI: 10.3233/JHD-160197

[8]Chudzik A, Śledzianowski A, Przybyszewski AW. Machine learning and digital biomarkers can detect early stages of neurodegenerative diseases. Sensors (Basel), 2024, 24(5), 1572. DOI: 10.3390/s24051572

[9]Song J, Cho E, Lee H, Lee S, Kim S, Kim J. Development of neurodegenerative disease diagnosis and monitoring from traditional to digital biomarkers. Biosensors (Basel), 2025, 15(2), 102. DOI: 10.3390/bios15020102

[10]Li H, Zecca M, Huang J. Evaluating the utility of wearable sensors for the early diagnosis of Parkinson disease: Systematic review. Journal of Medical Internet Research, 2025, 27, e69422. DOI: 10.2196/69422

[11]Subbaswamy A, Saria S. From development to deployment: Dataset shift, causality, and shift-stable models in health AI. Biostatistics, 2020, 21(2), 345-352. DOI: 10.1093/biostatistics/kxz041

[12]Finlayson SG, Subbaswamy A, Singh K, Bowers J, Kupke A, Zittrain J, et al. The clinician and dataset shift in artificial intelligence. The New England Journal of Medicine, 2021, 385(3), 283-286. DOI: 10.1056/NEJMc2104626

[13]Davis SE, Greevy RA Jr, Fonnesbeck C, Lasko TA, Walsh CG, Matheny ME. A nonparametric updating method to correct clinical prediction model drift. Journal of the American Medical Informatics Association, 2019, 26(12), 1448-1457. DOI: 10.1093/jamia/ocz127

[14]Chekroud AM, Hawrilenko M, Loho H, Bondar J, Gueorguieva R, Hasan A, et al. Illusory generalizability of clinical prediction models. Science, 2024, 383(6679), 164-167. DOI: 10.1126/science.adg8538

[15]U.S. Food and Drug Administration. Digital health technologies for remote data acquisition in clinical investigations: Guidance for industry, investigators, and other stakeholders. Silver Spring (MD): FDA. 2023. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/digital-health-technologies-remote-data-acquisition-clinical-investigations

[16]Warmerdam E, Hausdorff JM, Atrsaei A, Zhou Y, Mirelman A, Aminian K, et al. Long-term unsupervised mobility assessment in movement disorders. The Lancet Neurology, 2020, 19(5), 462-470. DOI: 10.1016/S1474-4422(19)30397-7

[17]Bent B, Goldstein BA, Kibbe WA, Dunn JP. Investigating sources of inaccuracy in wearable optical heart rate sensors. npj Digital Medicine, 2020, 3, 18. DOI: 10.1038/s41746-020-0226-6

[18]Onnela JP, Rauch SL. Harnessing smartphone-based digital phenotyping to enhance behavioral and mental health. Neuropsychopharmacology, 2016, 41(7), 1691-1696. DOI: 10.1038/npp.2016.7

[19]Moreno-Torres JG, Raeder T, Alaiz-Rodríguez R, Chawla NV, Herrera F. A unifying view on dataset shift in classification. Pattern Recognition, 2012, 45(1), 521-530. DOI: 10.1016/j.patcog.2011.06.019

[20]Quiñonero-Candela J, Sugiyama M, Schwaighofer A, Lawrence ND, editors. Dataset shift in machine learning. Cambridge (MA): MIT Press, 2009. DOI: 10.7551/mitpress/9780262170055.001.0001

[21]Gama J, Žliobaitė I, Bifet A, Pechenizkiy M, Bouchachia A. A survey on concept drift adaptation. ACM Computing Surveys, 2014, 46(4), 44. DOI: 10.1145/2523813

[22]Lipton ZC, Wang YX, Smola AJ. Detecting and correcting for label shift with black box predictors. Proceedings of the 35th International Conference on Machine Learning, 2018, 80, 3122-3130. Available from: https://proceedings.mlr.press/v80/lipton18a.html

[23]Rudroff T. The dual diversity crisis in physiology. The Journal of Physiology, 2026, 604(12), 4626-4630. DOI: 10.1113/JP290947

[24]Davis SE, Lasko TA, Chen G, Siew ED, Matheny ME. Calibration drift in regression and machine learning models for acute kidney injury. Journal of the American Medical Informatics Association, 2017, 24(6), 1052-1061. DOI: 10.1093/jamia/ocx030

[25]Van Calster B, McLernon DJ, van Smeden M, Wynants L, Steyerberg EW. Calibration: The Achilles heel of predictive analytics. BMC Medicine, 2019, 17(1), 230. DOI: 10.1186/s12916-019-1466-7

[26]Fisher AJ, Medaglia JD, Jeronimus BF. Lack of group-to-individual generalizability is a threat to human subjects research. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115(27), E6106-E6115. DOI: 10.1073/pnas.1711978115

[27]Rudroff T. Frontal-striatal glucose metabolism and fatigue in patients with multiple sclerosis, long COVID, and COVID-19 recovered controls. Experimental Brain Research, 2024, 242(9), 2125-2136. DOI: 10.1007/s00221-024-06882-z

[28]Rudroff T. Digital biomarkers and AI for remote monitoring of fatigue progression in neurological disorders: Bridging mechanisms to clinical applications. Brain Sciences, 2025, 15(5), 533. DOI: 10.3390/brainsci15050533

[29]Goldsack JC, Coravos A, Bakker JP, Bent B, Dowling AV, Fitzer-Attas C, et al. Verification, analytical validation, and clinical validation (V3): The foundation of determining fit-for-purpose for biometric monitoring technologies (BioMeTs). npj Digital Medicine, 2020, 3, 55. DOI: 10.1038/s41746-020-0260-4

[30]Bakker JP, Barge R, Centra J, Cobb B, Cota C, Guo CC, et al. V3+ extends the V3 framework to ensure user-centricity and scalability of sensor-based digital health technologies. npj Digital Medicine, 2025, 8(1), 51. DOI: 10.1038/s41746-024-01322-2

[31]Evers LJW, Krijthe JH, Meinders MJ, Bloem BR, Heskes TM. Measuring Parkinson's disease over time: The real-world within-subject reliability of the MDS-UPDRS. Movement Disorders, 2019, 34(10), 1480-1487. DOI: 10.1002/mds.27790

[32]Adams JL, Kangarloo T, Gong Y, Khachadourian V, Tracey B, Volfson D, et al. Using a smartwatch and smartphone to assess early Parkinson's disease in the WATCH-PD study over 12 months. Journal of Parkinson's Disease, 2024, 10(1), 112. DOI: 10.1038/s41531-024-00721-2

[33]Sotirakis C, Su Z, Brzezicki MA, Conway N, Tarassenko L, FitzGerald JJ, et al. Identification of motor progression in Parkinson's disease using wearable sensors and machine learning. Journal of Parkinson's Disease, 2023, 9, 142. DOI: 10.1038/s41531-023-00581-2

[34]Templeton JM, Poellabauer C, Schneider S, Rahimi M, Braimoh T, Tadamarry F, et al. Modernizing the staging of Parkinson disease using digital health technology. Journal of Medical Internet Research, 2025, 27, e63105. DOI: 10.2196/63105

[35]Schalkamp AK, Peall KJ, Harrison NA, Sandor C. Wearable movement-tracking data identify Parkinson's disease years before clinical diagnosis. Nature Medicine, 2023, 29(8), 2048-2056. DOI: 10.1038/s41591-023-02440-2

[36]Stegmann GM, Hahn S, Liss J, Shefner J, Rutkove S, Shelton K, et al. Early detection and tracking of bulbar changes in ALS via frequent and remote speech analysis. npj Digital Medicine, 2020, 3, 132. DOI: 10.1038/s41746-020-00335-x

[37]Berron D, Glanz W, Clark L, Basche K, Grande X, Güsten J, et al. A remote digital memory composite to detect cognitive impairment in memory clinic samples in unsupervised settings using mobile devices. npj Digital Medicine, 2024, 7(1), 79. DOI: 10.1038/s41746-024-00999-9

[38]van den Berg RL, van der Landen SM, Keijzer MJ, van Gils AM, van Dam M, Ziesemer KA, et al. Smartphone- and tablet-based tools to assess cognition in individuals with preclinical Alzheimer disease and mild cognitive impairment: Scoping review. Journal of Medical Internet Research, 2025, 27, e65297. DOI: 10.2196/65297

[39]Stisen A, Blunck H, Bhattacharya S, Prentow TS, Kjærgaard MB, Dey A, et al. Smart devices are different: Assessing and mitigating mobile sensing heterogeneities for activity recognition. In: Proceedings of the 13th ACM Conference on Embedded Networked Sensor Systems (SenSys '15). New York: ACM, 2015, 127-140. DOI: 10.1145/2809695.2809718

[40]Bianchini E, Rinaldi D, De Carolis L, Galli S, Alborghetti M, Hansen C, et al. Reliability of average daily steps measured through a consumer smartwatch in Parkinson disease phenotypes, stages, and severities: Cross-sectional study. JMIR Formative Research, 2025, 9, e63153. DOI: 10.2196/63153

[41]Rookes TA, Batla A, Armstrong M, Ambler G, Walters K, Schrag A. Patient acceptability and technical reliability of wearable devices used for monitoring people with Parkinson disease: Survey study. JMIR Formative Research, 2025, 9, e63704. DOI: 10.2196/63704

[42]Kirk C, Küderle A, Micó-Amigo ME, Bonci T, Paraschiv-Ionescu A, Ullrich M, et al. Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device. Scientific Reports, 2024, 14(1), 1754. DOI: 10.1038/s41598-024-51766-5

[43]Lozano-Garcia M, Doheny EP, Mann E, Morgan-Jones P, Drew C, Busse-Morris M, et al. Estimation of gait parameters in Huntington's disease using wearable sensors in the clinic and free-living conditions. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2024, 32, 2239-2349. DOI: 10.1109/TNSRE.2024.3407887

[44]Abbaspourazad S, Elachqar O, Miller AC, Emrani S, Nallasamy U, Shapiro I. Large-scale training of foundation models for wearable biosignals. In: Proceedings of the Twelfth International Conference on Learning Representations (ICLR 2024), 2024. Available from: https://arxiv.org/abs/2312.05409

[45]Little MA, McSharry PE, Hunter EJ, Spielman J, Ramig LO. Suitability of dysphonia measurements for telemonitoring of Parkinson's disease. IEEE Transactions on Biomedical Engineering, 2009, 56(4), 1015-1022. DOI: 10.1109/TBME.2008.2005954

[46]Clark A, Gresham G, Pevnick J, Duncan R, Kamrava M, Sobolev M. Predicting engagement patterns with connected wearable devices in a health system: Survival analysis. Journal of Medical Internet Research, 2025, 27, e78507. DOI: 10.2196/78507

[47]Ding H, Ho K, Searls E, Low S, Li Z, Rahman S, et al. Assessment of wearable device adherence for monitoring physical activity in older adults: Pilot cohort study. JMIR Aging, 2024, 7, e60209. DOI: 10.2196/60209

[48]Peterson CM, St Louis RM, Flannagan C. Enhancing enrollment and adherence in long-term wearable research on dementia: Qualitative systematic review and meta-synthesis. JMIR Aging, 2025, 8, e63768. DOI: 10.2196/63768

[49]Nunes AS, Pawlik M, Mishra RK, Waddell E, Coffey M, Tarolli CG, et al. Digital assessment of speech in Huntington disease. Frontiers in Neurology, 2024, 15, 1310548. DOI: 10.3389/fneur.2024.1310548

[50]Yang R, Gao S, Jiang Y. Digital divide as a determinant of health in the U.S. older adults: Prevalence, trends, and risk factors. BMC Geriatrics, 2024, 24(1), 1027. DOI: 10.1186/s12877-024-05612-y

[51]Jaana M, Tamim H, Paré G. eHealth and the digital divide among older Canadians: Insights from a national cross-sectional study. Journal of Medical Internet Research, 2025, 27, e72274. DOI: 10.2196/72274

[52]Li Y, Liu C, Sun J, Zhang J, Li X, Zhang Z. The digital divide and cognitive disparities among older adults: Community-based cohort study in China. Journal of Medical Internet Research, 2024, 26, e59684. DOI: 10.2196/59684

[53]Jones WS, Farrow DJ. One-class support vector machines for detecting population drift in deployed machine learning medical diagnostics. Scientific Reports, 2025, 15, 12157. DOI: 10.1038/s41598-025-94427-x

[54]Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al. The prevention and treatment of missing data in clinical trials. The New England Journal of Medicine, 2012, 367, 1355-1360. DOI: 10.1056/NEJMsr1203730

[55]Burq M, Rainaldi E, Ho KC, Chen C, Bloem BR, Evers LJW, et al. Virtual exam for Parkinson's disease enables frequent and reliable remote measurements of motor function. npj Digital Medicine, 2022, 5(1), 65. DOI: 10.1038/s41746-022-00607-8

[56]Fraser KC, Meltzer JA, Rudzicz F. Linguistic features identify Alzheimer's disease in narrative speech. Journal of Alzheimer's Disease, 2016, 49(2), 407-422. DOI: 10.3233/JAD-150520

[57]Lipsmeier F, Simillion C, Bamdadian A, et al. A remote digital monitoring platform to assess cognitive and motor symptoms in Huntington disease: Cross-sectional validation study. Journal of Medical Internet Research, 2022, 24(6), e32997. DOI: 10.2196/32997

[58]Kore A, Abbasi Bavil E, Subasri V, Abdalla M, Fine B, Dolatabadi E, et al. Empirical data drift detection experiments on real-world medical imaging data. Nature Communications, 2024, 15(1), 1887. DOI: 10.1038/s41467-024-46142-w

[59]Koch LM, Baumgartner CF, Berens P. Distribution shift detection for the postmarket surveillance of medical AI algorithms: a retrospective simulation study. npj Digital Medicine, 2024, 7, 120. DOI: 10.1038/s41746-024-01085-w

[60]Sahiner B, Chen W, Samala RK, Petrick N. Data drift in medical machine learning: Implications and potential remedies. The British Journal of Radiology, 2023, 96(1150), 20220878. DOI: 10.1259/bjr.20220878

[61]Nestor B, McDermott MBA, Boag W, Berner G, Naumann T, Hughes MC, et al. Feature robustness in non-stationary health records: Caveats to deployable model performance in common clinical machine learning tasks. Proceedings of Machine Learning Research, 2019, 106, 381-405. Available from: https://proceedings.mlr.press/v106/nestor19a.html

[62]Ramspek CL, Jager KJ, Dekker FW, Zoccali C, van Diepen M. External validation of prognostic models: What, why, how, when and where? Clinical Kidney Journal, 14(1), 49-58. DOI: 10.1093/ckj/sfaa188

[63]Zhang X, Xue Y, Su X, Chen S, Liu K, Chen W, et al. A transfer learning approach to correct the temporal performance drift of clinical prediction models: Retrospective cohort study. JMIR Medical Informatics, 2022, 10(11), e38053. DOI: 10.2196/38053

[64]Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): Explanation and elaboration. Annals of Internal Medicine, 2015, 162, W1-W73. DOI: 10.7326/M14-0698

[65]Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, et al. TRIPOD+AI statement: Updated guidance for reporting clinical prediction models that use regression or machine learning methods. The BMJ, 2024, 385, e078378. DOI: 10.1136/bmj-2023-078378

[66]Nouri S, Khoong EC, Lyles CR, Karliner L. Addressing equity in telemedicine for chronic disease management during the Covid-19 pandemic. NEJM Catalyst Innovations in Care Delivery, 2020, 1(3), 1-13. DOI: 10.1056/CAT.20.0123

[67]Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science, 2019, 366(6464), 447-453. DOI: 10.1126/science.aax2342

[68]Lekadir K, Frangi AF, Porras AR, Glocker B, Cintas C, Langlotz CP, et al. FUTURE-AI: International consensus guideline for trustworthy and deployable artificial intelligence in healthcare. The BMJ, 2025, 388, e081554. DOI: 10.1136/bmj-2024-081554

[69]U.S. Food and Drug Administration. Artificial intelligence/machine learning (AI/ML)-based software as a medical device (SaMD) action plan. Silver Spring (MD): FDA, 2021. Available from: https://www.fda.gov/media/145022/download

[70]U.S. Food and Drug Administration, Health Canada, Medicines and Healthcare products Regulatory Agency. Predetermined change control plans for machine learning-enabled medical devices: Guiding principles. 2023. Available from: https://www.fda.gov/medical-devices/software-medical-device-samd/predetermined-change-control-plans-machine-learning-enabled-medical-devices-guiding-principles

[71]U.S. Food and Drug Administration. Marketing submission recommendations for a predetermined change control plan for artificial intelligence-enabled device software functions: Guidance for industry and Food and Drug Administration staff. Silver Spring (MD): FDA, 2024. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-submission-recommendations-predetermined-change-control-plan-artificial-intelligence

[72]U.S. Food and Drug Administration. Artificial intelligence-enabled device software functions: Lifecycle management and marketing submission recommendations. Draft guidance for industry and Food and Drug Administration staff. Silver Spring (MD): FDA, 2025. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/artificial-intelligence-enabled-device-software-functions-lifecycle-management-and-marketing

[73]European Parliament and Council of the European Union. Regulation (EU) 2024/1689 laying down harmonised rules on artificial intelligence (Artificial Intelligence Act). Official Journal of the European Union, 2024. Available from: https://eur-lex.europa.eu/eli/reg/2024/1689/oj

[74]Youssef A, Pencina M, Thakur A, Zhu T, Clifton D, Shah NH. External validation of AI models in health should be replaced with recurring local validation. Nature Medicine, 2023, 29(11), 2686-2687. DOI: 10.1038/s41591-023-02540-z

[75]Rabanser S, Günnemann S, Lipton ZC. Failing loudly: an empirical study of methods for detecting dataset shift. In: Advances in Neural Information Processing Systems 32 (NeurIPS 2019), 2019. Available from: https://arxiv.org/abs/1810.11953

[76]Lee CS, Lee AY. Clinical applications of continual learning machine learning. Lancet Digit Health, 2020, 2(6), e279-e281. DOI: 10.1016/S2589-7500(20)30102-3

[77]Feng J, Phillips RV, Malenica I, Bishara A, Hubbard AE, Celi LA, et al. Clinical artificial intelligence quality improvement: Towards continual monitoring and updating of AI algorithms in healthcare. npj Digital Medicine, 2022, 5(1), 66. DOI: 10.1038/s41746-022-00611-y

[78]Verhoef C, Gommers D, van de Sande D, van Genderen ME, Hilling DE, Daams F, et al. Importance of model governance in clinical AI models: Case study on the relevance of data drift detection. BMJ Digital Health & AI, 2025, 1(1), e000046. DOI: 10.1136/bmjdhai-2025-000046

[79]Arjovsky M, Bottou L, Gulrajani I, Lopez-Paz D. Invariant risk minimization. arXiv, 2019. Available from: https://arxiv.org/abs/1907.02893

[80]Castro DC, Walker I, Glocker B. Causality matters in medical imaging. Nature Communications, 2020, 11, 3673. DOI: 10.1038/s41467-020-17478-w

[81]Guo LL, Pfohl SR, Fries J, Posada J, Fleming SL, Aftandilian C, et al. Systematic review of approaches to preserve machine learning performance in the presence of temporal dataset shift in clinical medicine. Applied Clinical Informatics, 2021, 12(4), 808-815. DOI: 10.1055/s-0041-1735184

[82]Austin JA, Lobo EH, Samadbeik M, Engstrom T, Philip R, Pole JD, et al. Decades in the making: The evolution of digital health research infrastructure through synthetic data, common data models, and federated learning. Journal of Medical Internet Research, 2024, 26, e58637. DOI: 10.2196/58637

[83]Tanim SA, Aurnob AR, Mridha MF, Safran M, Alfarhood S, Che D. Secure federated learning for Parkinson's disease: Non-IID data partitioning and homomorphic encryption strategies. IEEE Access, 2024, 12, 127309-127327. DOI: 10.1109/ACCESS.2024.3454690

Downloads

Published

2026-11-16

Issue

Section

Articles

How to Cite

Olaitan Ebenezer Oluwadare, Ameh, A. D., Yakubu, A.-B. ., & Sunday, F. U. . (2026). When Digital Biomarkers Drift: A Critical Review of Temporal, Technological, Behavioral, and Population Instability in AI Models for Neurodegenerative Disease. Neuroscience Research and Clinical Practice, 2(2), 1-24. https://doi.org/10.64229/8m5kv497